» Articles » PMID: 1908091

Antibodies to Poly[(2----8)-alpha-N-acetylneuraminic Acid] and Poly[(2----9)-alpha-N-acetylneuraminic Acid] Are Elicited by Immunization of Mice with Escherichia Coli K92 Conjugates: Potential Vaccines for Groups B and C Meningococci and E. Coli K1

Overview
Specialty Science
Date 1991 Aug 15
PMID 1908091
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Meningitis and other systemic infections caused by group B Neisseria meningitidis and Escherichia coli K1 remain important problems. The capsular polysaccharides (CPs) of these pathogens (poly[(2----8)-alpha-N-acetylneuraminic acid] or poly(alpha 2-8NeuNAc] are identical and are virulence factors and protective antigens for both. CP vaccines for these pathogens are not available because poly(alpha 2-8NeuNAc) alone, as a complex or a conjugate, is poorly immunogenic. Because oligomers of poly(alpha 2-8NeuNAc) in fetal brain and other tissues bind antibodies in vitro, it has been suggested that antibodies to this CP might be pathologic. We synthesized conjugates of this CP with tetanus toxoid under conditions that avoid lactone formation. Using this scheme, we also synthesized conjugates of group C meningococcal CP (poly[(2----9)-alpha-N-acetylneuraminic acid] or poly(alpha 2-9NeuNAc] and of E. coli K92 CP [poly(alpha 2-8, alpha 2-9NeuNAc)]. When injected s.c. in saline into mice, conjugates of poly(alpha 2-8NeuNAc) or poly(alpha 2-9NeuNAc) elicited homologous antibodies. E. coli K92 conjugates elicited both poly(alpha 2-8NeuNAc) and poly(alpha 2-9NeuNAc) antibodies. Both components of the conjugates expressed T-dependent immunologic properties under conditions and dosages acceptable for clinical evaluation. Poly(alpha 2-8NeuNAc) antibodies elicited by the homologous or the K92 conjugates had lower binding activities at 37 degrees C than at 22 degrees C. "Natural" poly(alpha 2-8NeuNAc) antibodies were present in almost all matched pairs of human maternal and cord sera; most cord levels were higher than in corresponding maternal sera. These findings suggest that increased levels of poly(alpha 2-8NeuNAc) IgG antibodies elicited by our conjugates will confer protective immunity to group B meningococci and E. coli K1 and will not be pathologic.

Citing Articles

Siglecs at the Host-Pathogen Interface.

Chang Y, Nizet V Adv Exp Med Biol. 2020; 1204:197-214.

PMID: 32152948 PMC: 7121523. DOI: 10.1007/978-981-15-1580-4_8.


Conjugation of Meningococcal Lipooligosaccharides Through Their Non-Reducing Terminus Results in Improved Induction a Protective Immune Response.

Mieszala M, Jennings H, Drab M, Gamian A Arch Immunol Ther Exp (Warsz). 2019; 67(4):237-248.

PMID: 31030218 PMC: 6597602. DOI: 10.1007/s00005-019-00542-9.


Exploration of the Sialic Acid World.

Schauer R, Kamerling J Adv Carbohydr Chem Biochem. 2018; 75:1-213.

PMID: 30509400 PMC: 7112061. DOI: 10.1016/bs.accb.2018.09.001.


X-ray crystallographic structure of a bacterial polysialyltransferase provides insight into the biosynthesis of capsular polysialic acid.

Lizak C, Worrall L, Baumann L, Pfleiderer M, Volkers G, Sun T Sci Rep. 2017; 7(1):5842.

PMID: 28724897 PMC: 5517516. DOI: 10.1038/s41598-017-05627-z.


The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).

Shea M Ann Med Surg (Lond). 2015; 2(2):53-6.

PMID: 25628885 PMC: 4306095. DOI: 10.1016/S2049-0801(13)70037-2.


References
1.
Saukkonen K, Haltia M, Frosch M, Bitter-Suerman D, Leinonen M . Antibodies to the capsular polysaccharide of Neisseria meningitidis group B or E. coli K1 bind to the brains of infant rats in vitro but not in vivo. Microb Pathog. 1986; 1(1):101-5. DOI: 10.1016/0882-4010(86)90036-7. View

2.
Raff H, Devereux D, Shuford W, Maloney G . Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections. J Infect Dis. 1988; 157(1):118-26. DOI: 10.1093/infdis/157.1.118. View

3.
Jennings H, Roy R, Gamian A . Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol. 1986; 137(5):1708-13. View

4.
Jennings H, Gamian A, Michon F, Ashton F . Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of group B Neisseria meningitidis and Escherichia coli K1. J Immunol. 1989; 142(10):3585-91. View

5.
ORSKOV I, ORSKOV F . Escherichia coli in extra-intestinal infections. J Hyg (Lond). 1985; 95(3):551-75. PMC: 2129573. DOI: 10.1017/s0022172400060678. View